Anterior Nutcracker Syndrome (NCS) can occur when the aorta and superior mesenteric artery compress the left renal vein. Loin pain hematuria syndrome (LPHS) occurs as kidney pain resulting from a past insult to the kidney, most commonly from nephrolithiasis. We herein present a case of previously treated NCS. Three months after treatment with GVT, the pelvic congestion was resolved but left flank pain continued concerning for undiagnosed Loin Pain Hematuria. Additionally, we present a treatment algorithm that provides a differential pathway for diagnosis and treatment of combined NCS and LPHS.

2019-06-04·Urologiia

Efficiency of immunomodulatotors for complex therapy of chronic recurrent cystitis in women

Article

作者: A V Kuzmenko ; T A Gyaurgiev ; V V Kuzmenko

INTRODUCTIONCurrently, chronic recurrent cystitis is one of the most important problems in urology. Considering the role of immune status disorders in the pathogenesis of inflammatory diseases, the use of immunocorrective drugs as part of the complex therapy is of particular relevance.AIMto study the efficiency of therapy for chronic recurrent bacterial cystitis in combination with immunomodulators (Galavit).MATERIALS AND METHODSA total of 60 women with acute stage of chronic recurrent bacterial cystitis were examined. The patients were randomized into 2 groups of 30 patients. In the control group, standard antibiotic therapy was administered. In the treatment group, patients received Galavit in combination with standard therapy. All patients were followed-up on the 1st, 5th and 10th day. Voiding diaries, chronobiological status and pain severity using a 5-point scale were evaluated. In addition, complete blood count, urinalysis, urine culture and enzyme immunoassay for determination of serum level of interleukin (IL) 1, IL-6, tumor necrosis factor (TNF-) were analyzed. A number of recurrences after 3 months of therapy was assessed.RESULTSComplex therapy in combination with Galavit in women with acute stage of chronic bacterial cystitis allows to decrease in desynchronosis by 20%, reduce pain by 2.5 times, frequency of urination by 1.7 times, the number of urgent voids and night urination by 2.4 and 5 times, respectively, by the 5th day of therapy. In the group of patients receiving immunomodulators a significantly more pronounced decrease in the level of IL-1, IL-6, TNF- and CRP was noted. During 3 months of follow-up, there were 2 recurrences in the control group and no recurrences in treatment group (10%).CONCLUSIONThe use of Galavit in the treatment of women with chronic recurrent bacterial cystitis has pathogenetic basis. A clear advantage of the drug is more rapid relief of symptoms, normalization of laboratory parameters, recovery of chronorhythms and the achievement of clinical remission.

2015-05-01·Georgian medical news

[Evolution of oxidant-antioxidant homeostasis in patients with eczema treated using different methods].

Article

作者: Denysenko, O ; Stepan, N

OBJECTIVEto study the evolution of the oxidant-antioxidant homeostasis indices in patients with eczema using various methods of treating dermatosis. The study involved 63 patients with eczema (34 - males, 28 - females), aged 18-67 years, who were determined indices of pro- and antioxidant systems of blood. Patients with eczema were divided into 3 groups that were prescribed different treatments: the first comparative group (21 patients) - received a standard therapy; the second comparative group (20 patients) - had a standard therapy and additionally an antioxidant preparation "Mexidol", the third (basic group) - 22 patients, who were prescribed a complex therapy with a combination of two drugs with antioxidant effect: "Mexidol" and "Galavit." It was established that multimodality therapy for eczema while using two drugs with antioxidant action ("Mexidol", "Galavit") contributes to the most significant positive dynamics and normalization of the studied parameters of oxidant-antioxidant homeostasis of patients compared to a standard therapy of dermatosis or its combination with antioxidant preparation "Mexidol".

100 项与鲁米诺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L03	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
妇科疾病	俄罗斯	Bach Pharma, Inc.	2011-11-22
免疫系统疾病	匈牙利	Bach Pharma, Inc.	2011-10-16
炎症	匈牙利	Bach Pharma, Inc.	2011-10-14

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
干眼综合征	临床2期	美国	Bach Pharma, Inc.	2011-10-31
干眼综合征	临床2期	德国	Bach Pharma, Inc.	2011-10-31
超敏反应	临床2期	美国	Bach Pharma, Inc.	2011-10-29
创伤和损伤	临床2期	俄罗斯	Bach Pharma, Inc.	2011-10-28
共济失调毛细血管扩张	临床2期	美国	Bach Pharma, Inc.	-
代谢综合征	临床2期	美国	Bach Pharma, Inc.	-
神经系统疾病	临床2期	澳大利亚	Bach Pharma, Inc.	-
帕金森病	临床2期	美国	Bach Pharma, Inc.	-
小细胞肺癌	药物发现	美国	Bach Pharma, Inc.	2011-10-18
乳腺癌	药物发现	美国	Bach Pharma, Inc.	2011-10-11